Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study

Table 1 The distribution of various cancers of the lung among the patients and the treatment regimens they received

Sex	Subtype 1	Subtype 2	Stage	Treatment (N)	N	N	N	N
Sex	Subtype 1	Subtype 2	Stage	Treatment (N)	T0	T1	T3	T6
Male	SCLC		IIIA	CE + R (1)	1	1	1	0
	SCLC		IIIB	CE + R (1)	1	1	1	1
	SCLC		IV	CE (1)	1	1	1	1
	MM		IV	CP (2)	2	2	2	1
	NSCLC	NSCC	IIIA	CD + R (1)	1	1	1	1
		NSCC	IV	CD + R (1), CP (11)^a	12	12	10	8
		SCC	IIIB	CD + R (1), CG (1)	2	2	2	2
Female	NSCLC	NSCC	IIIA	CV (1)	1	1	1	1
		NSCC	IIIB	CP (1)	1	1	1	0
		NSCC	IV	CP (2)	2	2	2	2

Lung cancer: SCLC small cell lung cancer, MM mesothelioma of the lung, NSCLC non-small cell lung cancer, SCC squamous cell carcinoma of the lung, and NSCC Non squamous cell carcinoma
Treatment: CD cisplatin & docetaxel, CE cisplatin & etoposide, CG cisplatin & gemcitabine, CP cisplatin & pemetrexed, CV cisplatin & vinorelbine, R radiotherapy
N Number of recipients for a particular chemotherapy regimen
^aThe number of participants reduced to 10 and 8 at the 3^rd and 6^th months respectively

ISSN: 1471-2407